Science news articles about 'tyrosine kinases'EGFR protects cancer cells from starvation via a kinase-independent mechanism
... level of EGFR in cancer tissues is correlated with prognosis, but not with responsiveness to EGFR tyrosine kinase inhibitor treatment, suggesting that, independent of its kinase activity, EGFR may ... Activation of LYN kinase is associated with imatinib-resistance in CML patients
... BCR-ABL point mutations and support the use of other tyrosine kinase inhibitors to treat a broad spectrum ... geting both BCR-ABL and LYN kinases may prove beneficial in certain circumstances of imatinib ... Arsenic-based therapy shown to help eradicate leukemia-initiating cells
... of stem cell disorders. CML is typically treated with the targeted therapy imatinib (Gleevec), a tyrosine kinase inhibitor.
“Gleevec does dramatically improve prognosis of CML patients,” notes ... Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, said Massimo Cristofanilli, M. ... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, to become commercially available ... Can you hear me now?
... than anything previously seen in animals, which may help scientists understand the fundamentals of how all tyrosine kinase signaling works. Despite their extreme diversity, Monosiga kinases time and ... Overcoming inhibitors of cell death improves cancer therapy efficacy
... . Although pre-clinical studies indicated therapeutics inhibiting a group of proteins known as receptor tyrosine kinases (RTKs) would likely be beneficial to individuals with ... Monash researchers uncover cancer survival secrets
... and Molecular Biology at Monash University said their work showed that the enzymes known as protein tyrosine kinases (PTKs) had a greater role than previously thought in the rate of growth and tumour ... CSHL scientists identify new drug target against virulent type of breast cancer
... to test."
ErbB2 and Brk go hand-in-hand
ErbB2 is a member of a family of enzymes called receptor tyrosine kinases -- cell-surface molecules that goad cells into proliferating when ... Massive cancer gene search finds potential new targets in brain tumors
... tumor suppressor pathway, which is involved in response to DNA damage and cell death; and the receptor tyrosine kinase pathway that carries signals that control cell growth.
Chin said that the most ... Significant benefits in non-small-cell lung cancer from customizing erlotinib treatment
... of lung cancer.
The two mutations they screened for were a deletion in exon 19 of the receptor's tyrosine kinase domain, and a mutation in exon 21. Tumors with EGFR mutations are more frequently ... Study establishes role for gefitinib in Asian nonsmokers with lung cancer
... University of Hong Kong.
"Currently, gefitinib and other EGFR tyrosine kinase inhibitors are considered as second line therapy for advanced non-small-cell lung cancers, meaning ... A promising approach in the prevention and treatment of pancreatic cancer
... a potential therapeutic strategy for pancreatic cancer has been developed. Erlotinib is a small molecule tyrosine kinase inhibitor that efficiently blocks EGFR. Preliminary results of phase III trial ... Researcher at NYU Langone's Skirball Institute available to discuss finding published in Cell
... the long-standing mystery of what Agrin binds to at the developing junction to activate the receptor tyrosine kinase MuSK," says molecular biologist Martin Raff of the MRC laboratory for Molecular ... Getting to grips with the complexity of disease proteins
... operates as a giant molecular machine, with each part in close communication with the others.
"It is clear that tyrosine kinase inhibitors do not simply inhibit the enzyme, but rather remodel the ... Large-scale genetic study sheds new light on lung cancer
... kinases (ERBB4, KDR and FGFR4). These genes code for cell receptors coupled to members of the tyrosine kinase family of enzymes, which are considered prime targets for new cancer therapies.
After ...
Want to learn more? Search for tyrosine kinases
Return to e! Science News homepage for the latest science news
EGFR protects cancer cells from starvation via a kinase-independent mechanism
... level of EGFR in cancer tissues is correlated with prognosis, but not with responsiveness to EGFR tyrosine kinase inhibitor treatment, suggesting that, independent of its kinase activity, EGFR may ...Activation of LYN kinase is associated with imatinib-resistance in CML patients
... BCR-ABL point mutations and support the use of other tyrosine kinase inhibitors to treat a broad spectrum ... geting both BCR-ABL and LYN kinases may prove beneficial in certain circumstances of imatinib ...Arsenic-based therapy shown to help eradicate leukemia-initiating cells
... of stem cell disorders. CML is typically treated with the targeted therapy imatinib (Gleevec), a tyrosine kinase inhibitor. “Gleevec does dramatically improve prognosis of CML patients,” notes ...Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, said Massimo Cristofanilli, M. ... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, to become commercially available ...Can you hear me now?
... than anything previously seen in animals, which may help scientists understand the fundamentals of how all tyrosine kinase signaling works. Despite their extreme diversity, Monosiga kinases time and ...Overcoming inhibitors of cell death improves cancer therapy efficacy
... . Although pre-clinical studies indicated therapeutics inhibiting a group of proteins known as receptor tyrosine kinases (RTKs) would likely be beneficial to individuals with ...Monash researchers uncover cancer survival secrets
... and Molecular Biology at Monash University said their work showed that the enzymes known as protein tyrosine kinases (PTKs) had a greater role than previously thought in the rate of growth and tumour ...CSHL scientists identify new drug target against virulent type of breast cancer
... to test." ErbB2 and Brk go hand-in-hand ErbB2 is a member of a family of enzymes called receptor tyrosine kinases -- cell-surface molecules that goad cells into proliferating when ...Massive cancer gene search finds potential new targets in brain tumors
... tumor suppressor pathway, which is involved in response to DNA damage and cell death; and the receptor tyrosine kinase pathway that carries signals that control cell growth. Chin said that the most ...Significant benefits in non-small-cell lung cancer from customizing erlotinib treatment
... of lung cancer. The two mutations they screened for were a deletion in exon 19 of the receptor's tyrosine kinase domain, and a mutation in exon 21. Tumors with EGFR mutations are more frequently ...Study establishes role for gefitinib in Asian nonsmokers with lung cancer
... University of Hong Kong. "Currently, gefitinib and other EGFR tyrosine kinase inhibitors are considered as second line therapy for advanced non-small-cell lung cancers, meaning ...A promising approach in the prevention and treatment of pancreatic cancer
... a potential therapeutic strategy for pancreatic cancer has been developed. Erlotinib is a small molecule tyrosine kinase inhibitor that efficiently blocks EGFR. Preliminary results of phase III trial ...Researcher at NYU Langone's Skirball Institute available to discuss finding published in Cell
... the long-standing mystery of what Agrin binds to at the developing junction to activate the receptor tyrosine kinase MuSK," says molecular biologist Martin Raff of the MRC laboratory for Molecular ...Getting to grips with the complexity of disease proteins
... operates as a giant molecular machine, with each part in close communication with the others. "It is clear that tyrosine kinase inhibitors do not simply inhibit the enzyme, but rather remodel the ...Large-scale genetic study sheds new light on lung cancer
... kinases (ERBB4, KDR and FGFR4). These genes code for cell receptors coupled to members of the tyrosine kinase family of enzymes, which are considered prime targets for new cancer therapies. After ...